Clinical Research Malaysia has signed a charter agreement with Syneos Health, to include CRM-affiliated clinical research sites under the Syneos Health Catalyst Program.
The Syneos Health Catalyst Program brings together clinical research sites and industry partners to deliver consistent quality in clinical trials. Sites under the program have the opportunity to participate in an increased volume of clinical trials as well as harness best practices and insights from other clinical research sites across the globe.
With the inking of this partnership, research sites in Malaysia will form Syneos Health’s first Catalyst Site Network in the Asia Pacific region. Sites within the network would benefit from increased access to clinical trials managed by Syneos Health in addition to improved efficiencies in study operations.
The charter agreement was signed at the Ministry of Health office in Putrajaya between General Manager and Regional Head of Asia Pacific Dr Ken Lee and the Chief Executive Officer of Clinical Research Malaysia (CRM) Dr Akhmal Yusof.
“This partnership is one of the many ongoing efforts by CRM to strengthen the country’s clinical research footprints. With more than 2000 sponsored clinical research conducted since 2012 in Malaysia, this collaboration would unlock new opportunities in bettering the quality of clinical trials and discovery of new treatments and local drugs.”, said Minister of Health Dr Zaliha Mustafa.
“Because of Malaysia’s clinical research achievements, it is natural for Syneos Health to be drawn here. We are seeing key drivers such as the start of the next wave of oncology biosimilars and cell and gene therapies put pressure on delivery. It is becoming essential we look to work with countries such as Malaysia in accelerating these new therapies to patients worldwide. A key part of this is to set up the framework of Catalyst in Malaysia.”, added Dr Ken Lee.
